multivirus (cmv, ebv, adv)-specific t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Aug 27, 2019 (NCT04832607)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Epstein-Barr nuclear antigen 1Immunity, passive
EBNA1 immunity, passive
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
- Human adenovirus type 2Immunity, passive
Human adenovirus type 2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04832607 | Phase 3 | Aug 27, 2019 | Bambino Gesù Hospital and Research Institute, European Commission, Ghent University, Leiden University, Ludwig Maximilians University, Miltenyi Biotec, Inc., Newcastle University, Simbec-Orion, University of Lorraine |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bambino Gesù Hospital and Research Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| European Commission | Government | 1 | 0 | 1 | 2019 |
| Ghent University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Ludwig Maximilians University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Miltenyi Biotec, Inc. | For profit | 1 | 0 | 1 | 2019 |
| Newcastle University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Simbec-Orion | For profit | 1 | 0 | 1 | 2019 |
| University of Lorraine | Academic/Hospital | 1 | 0 | 1 | 2019 |
9 organizations
Page 1 / 1